Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Kangchen Pharmaceutical (01681) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Index Inclusion - Kangchen Pharmaceutical will be added to the Hang Seng Composite Index, with the change taking effect after market close on March 6, 2026 [1] - The inclusion may lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1] Group 2: Share Buyback Plans - Kangchen Pharmaceutical's board has resolved to execute a share buyback plan with a total fund limit of up to HKD 200 million, to be conducted in the open market [1] - On January 29, 2026, the board approved an additional share buyback plan, increasing the total fund limit by up to HKD 100 million, bringing the total potential fund for share buybacks to a maximum of HKD 300 million [1] - The duration of the share buyback plan will last until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization [1]
康臣药业(01681)获纳入恒生综合指数 有望成为港股通标的